Cargando…

Cell-Surface Marker Signature for Enrichment of Ventricular Cardiomyocytes Derived from Human Embryonic Stem Cells

To facilitate understanding of human cardiomyocyte (CM) subtype specification, and the study of ventricular CM biology in particular, we developed a broadly applicable strategy for enrichment of ventricular cardiomyocytes (VCMs) derived from human embryonic stem cells (hESCs). A bacterial artificial...

Descripción completa

Detalles Bibliográficos
Autores principales: Veevers, Jennifer, Farah, Elie N., Corselli, Mirko, Witty, Alec D., Palomares, Karina, Vidal, Jason G., Emre, Nil, Carson, Christian T., Ouyang, Kunfu, Liu, Canzhao, van Vliet, Patrick, Zhu, Maggie, Hegarty, Jeffrey M., Deacon, Dekker C., Grinstein, Jonathan D., Dirschinger, Ralf J., Frazer, Kelly A., Adler, Eric D., Knowlton, Kirk U., Chi, Neil C., Martin, Jody C., Chen, Ju, Evans, Sylvia M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6135222/
https://www.ncbi.nlm.nih.gov/pubmed/30122443
http://dx.doi.org/10.1016/j.stemcr.2018.07.007
Descripción
Sumario:To facilitate understanding of human cardiomyocyte (CM) subtype specification, and the study of ventricular CM biology in particular, we developed a broadly applicable strategy for enrichment of ventricular cardiomyocytes (VCMs) derived from human embryonic stem cells (hESCs). A bacterial artificial chromosome transgenic H9 hESC line in which GFP expression was driven by the human ventricular-specific myosin light chain 2 (MYL2) promoter was generated, and screened to identify cell-surface markers specific for MYL2-GFP-expressing VCMs. A CD77(+)/CD200(−) cell-surface signature facilitated isolation of >97% cardiac troponin I-positive cells from H9 hESC differentiation cultures, with 65% expressing MYL2-GFP. This study provides a tool for VCM enrichment when using some, but not all, human pluripotent stem cell lines. Tools generated in this study can be utilized toward understanding CM subtype specification, and enriching for VCMs for therapeutic applications.